Etilevodopa
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
|
|
| Identifiers | |
| CAS Number | 37178-37-3  |
| ATC code | N04BA06 (combination with decarboxylase inhibitor) |
| PubChem | CID 170345 |
| ChemSpider | 148944 |
| UNII | 895X917GYE |
| KEGG | D04097 |
| Chemical data | |
| Formula | C11H15NO4 |
| Molar mass | 225.241 g/mol |
|
|
|
|
| (verify) | |
Etilevodopa (TV-1203) is a dopaminergic agent which was developed as a treatment for Parkinson's disease.[1] It is the ethyl ester of levodopa. It was never marketed.
See also[edit]
References[edit]
- ^ Djaldetti Ruth, Giladi Nir, Hassin-Baer Sharon, Shabtai Hertzel, Melamed Eldad (November–December 2003). "Pharmacokinetics of Etilevodopa Compared to Levodopa in Patient's With Parkinson's Disease: An Open-label, Randomized, Crossover Study". Clinical Neuropharmacology 26 (6): 322–326. doi:10.1097/00002826-200311000-00012.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
